Status:

COMPLETED

Rollover Study Of Lapatinib In Cancer Patients

Lead Sponsor:

GlaxoSmithKline

Conditions:

Neoplasms, Breast

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The EGF19060 study is a rollover study to evaluate the long term safety of lapatinib and to provide lapatinib to patients who had a positive response in previous lapatinib studies until lapatinib is a...

Eligibility Criteria

Inclusion

  • Currently receiving clinical benefit as defined by CR, PR or SD from treatment with lapatinib through participation in a Phase I study of lapatinib either as monotherapy or as part of a combination regimen.
  • Ability to understand and provide written informed consent to participate in this trial.
  • Is male or female.
  • Female and male subjects agree to the protocol specific birth control measures

Exclusion

  • Permanent discontinuation of lapatinib in the previous study due to intolerance or treatment failure.
  • Is a pregnant or lactating female.
  • Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations.
  • Currently receiving treatment with any medications listed on the prohibited medication list (see Section 7.2).
  • Has Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
  • Has a left ventricular ejection fraction (LVEF) \< 40% based on MUGA or ECHO.

Key Trial Info

Start Date :

August 19 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 5 2009

Estimated Enrollment :

31 Patients enrolled

Trial Details

Trial ID

NCT00169533

Start Date

August 19 2004

End Date

May 5 2009

Last Update

November 17 2017

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

GSK Investigational Site

Indianapolis, Indiana, United States, 46202

2

GSK Investigational Site

Detroit, Michigan, United States, 48201

3

GSK Investigational Site

Lebanon, New Hampshire, United States, 03756

4

GSK Investigational Site

Albuquerque, New Mexico, United States, 87131